Follicular Lymphoma Clinical Research Trials

Birmingham : Uab Comprehensive Cancer Center

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Huntsville : Clearview Cancer Institute

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Alhambra : Central Hematology Oncology Medical Group

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Burbank : Providence Saint Joseph Medical Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Corona : Compassionate Cancer Care Medical Group, Inc.

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Fountain Valley : Compassionate Cancer Care Medical Group, Inc.

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Fountain Valley : Lalita Pandit, MD Inc.

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Fullerton : St. Jude Medical Center

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Long Beach : Pacific Shores Medical Group

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Los Angeles : Santa Monica Hematology/Oncology

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Los Angeles : UCLA

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Los Angeles : Ucla-Division Of Hematology/Oncology

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Los Angeles : Usc - Norris Comprehensive Cancer Center And Hospital

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Redondo Beach : Cancer Care Associates Medical Group

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Santa Maria : Central Coast Medical Oncology

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Stanford : Stanford Cancer Center

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Colorado Springs : Memorial Hospital

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Grand Junction : St. Mary's Hospital Regional Cancer Center

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Southington : Cancer Center of Central Connecticut

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Boynton Beach : University Cancer Institute

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Boynton Beach : Collaborative Research Group, LLC

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Fort Lauderdale : Holy Cross Hospital

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Orlando : MD Anderson Cancer Center Orlando

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Atlanta : Emory University Winship Cancer Institute

A Phase I/II Trial of VR-CHOP in Lymphoma Patients

Atlanta : Winship Cancer Institute

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Hazard : Kentucky Cancer Clinic

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Baltimore : B. Douglas Smith, M.D.

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Fargo : Roger Maris Cancer Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Boston : Harvard Medical School-Mass General Hospital

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Boston : Massachusetts General Hospital

Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma

Boston : Dana-Farber Cancer Institute

Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma

Boston : Dana-Farber Cancer Institute

Oral Clofarabine for Relapsed/Refractory Indolent B-cell NHL and Mantle Cell Lymphoma

Boston : Massachusetts General Hospital

Oral Clofarabine for Relapsed/Refractory Indolent B-cell NHL and Mantle Cell Lymphoma

Boston : Novartis Investigative Site

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Ann Arbor : University of Michigan

Trial of Low-Dose MTX and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma

St. Louis : Washington University School of Medicine Siteman Cancer Center Hematology Labs

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

St. Louis : Washington University School of Medicine

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Denville : Oncology and Hematology Specialist

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Hackensack : John Theurer Cancer Center Hackensack University Medical Center

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Morristown : Hematology-Oncology Associates of North New Jersey

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Somerville : Somerset Hematology Oncology Associates

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

New York : Weill Cornell Medical College

Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

New York : St. Luke's-Roosevelt Hospital Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

New York : Montefiore Medical Center

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

New York : St-Luke's Roosevelt Hospital

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

New York : Weill Cornell -New York Presbyterian Hospital

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Durham : Duke University Medical Center

Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Durham : Novartis Investigative Site

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Columbus : South Carolina Oncology Associates

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Chattanooga : Chattanooga Hem/Oncology Ass (SCRI)

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Chattanooga : Novartis Investigative Site

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Nashville : Sarah Cannon Cancer Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Nashville : Sarah Cannon Research Institute

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Dallas : Baylor Sammons Cancer Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Houston : MD Anderson Cancer Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Houston : The University Of Texas Md Anderson Cancer Center

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Charlottesville : University of Virginia Medical Center

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Richmond : Virginia Cancer Center

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Seattle : Seattle Cancer Care Alliance

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Seattle : Seattle Cancer Care Alliance

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Seattle : University Of Washington

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Madison : University of Wisconsin

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Prahran : Novartis Investigative Site

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Gent : Novartis Investigative Site

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Leuven : Novartis Investigative Site

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Sofia : Merck Sharp & Dohme IDEA Inc.

Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001 AM2)

Toronto : Novartis Investigative Site

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Brest : CHU Morvan

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Creteil : Novartis Investigative Site

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Dijon : Hôpital d'Enfants - CHU Dijon

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Nantes : Hôpital Hôtel-Dieu

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Pierre Benite : Centre Hospitalier de Lyon Sud

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Rouen : Centre Henri Bequerel

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Tours : CHU Bretonneau - Centre Kaplan

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Berlin : Charité Campus Virchow Klinikum

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Essen : Universitätsklinikum Essen

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Gießen : Klinikum der Justus-Liebig-Universität

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Köln : Uniklinik Köln

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Mainz : Universitätsmedizin Mainz

Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma

München : Klinikum der Universität München-Großhadern

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Ulm : Universitatsklinikum Ulm

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Aviano : IRCCS Centro di Riferimento Oncologico

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Bologna : Azienda Ospedaliera di Bologna - Policlinico S. Orsola Malpighi

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Pescara : Novartis Investigative Site

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Pisa : Novartis Investigative Site

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Reggio Calabria : Novartis Investigative Site

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Torino : Novartis Investigative Site

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Akita :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Chuo-ku :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Fukuoka :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hidaka :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Isehara :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Izumo :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kagoshima :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kanazawa :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kurashiki :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kurume :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kyoto :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Maebashi :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Matsuyama :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Nagoya :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Ninomaru :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Sapporo :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Sendai :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Shikata-cho :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kuching : Investigative site

GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma

Amsterdam : Novartis Investigative Site

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Makati City : Merck Sharp & Dohme (I.A.) Corporation

Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001 AM2)

Gdansk : Uniwersyteckie Centrum Kliniczne

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Kraków : Małopolskie Centrum Medyczne

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Warsaw : Centrum Onkologii w Warszawie

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Warszawa : MSD Polska Sp. z o.o. Dzial Medyczny

Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001 AM2)

Barcelona : Novartis Investigative Site

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Madrid : Novartis Investigative Site

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Kiev : Merck Sharp & Dohme IDEA, Inc.

Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001 AM2)

Aberdeen : Aberdeen Royal Infirmary